INTRODUCTION AND OBJECTIVES:
Prostate MRI is commonly used to evaluate a rising PSA after a prostate biopsy. However, the optimal timing of post-biopsy MRI is debated due to conflicting reports on the incidence of post-biopsy hematoma. Here we query a large institutional cohort to determine the optimal timing of post-biopsy prostate MRI.
METHODS: Men undergoing a multiparametric prostate MRI (with T1, T2, diffusion weighted, and dynamic contrast enhanced sequences) between 2002-2013 at our institution prior to radical prostatectomy were identified. Men without a prior prostate biopsy and men with prior prostate cancer treatment were excluded. Endorectal coils were used with both 1.5T and 3T scanners. Hemorrhage was identified primarily using T1 sequences. Time from biopsy was modeled as a continuous variable in univariable and multivariable logistic regression. Youden 0 s J statistic was calculated to determine the time point after biopsy associated with the most discriminative value in terms of hematoma on MRI.
RESULTS: In a cohort of 396 men undergoing a staging prostate MRI, median time from prostate biopsy to MRI was 61 days and 27% (N[107) had prostate hematoma artifact on MRI. Increasing time from prostate biopsy to MRI was significantly associated with a reduced rate of visible prostate hematoma (Figure 1 ). On univariate logistic regression, each month between prostate biopsy and MRI was associated with reduced odds of visible prostate hematoma (OR 0.90, 0.84-0.97, p<0.01). On multivariable logistic regression, time from prostate biopsy remained the only significant association with visible prostate hematoma, despite adjusting for number of prior biopsy cores, age, cT stage, T3 vs T1.5 magnet, and PSA. A threshold of 51 days after prostate biopsy maximized the Youden index and had the most discriminative value with respect to visible hematoma rates. Patients undergoing an MRI within 51 days of MRI had a 37% chance of hematoma compared to 19.5% for those undergoing MRI after at least 51 days from biopsy (p<0.01).
CONCLUSIONS: Time from prostate biopsy was the only determinant of visible hematoma on MRI in our dataset. Waiting more than 50 days from biopsy to MRI was the optimal threshold to minimize hematoma rates. This data can assist with patient counseling for the timing of MRI after a prostate biopsy.
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MP09-02 ADDED VALUE OF MPMRI, MRI-TARGETED AND SYSTEMATIC BIOPSY IN THE PREDICTION OF ADVERSE PATHOLOGIC FEATURES IN CONTEMPORARY PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY
INTRODUCTION AND OBJECTIVES: Available models predicting extracapsular extension (ECE) and seminal vesicle invasion (SVI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) are limited by two main factors: (i) they do not incorporate multiparametric MRI (mpMRI) and (ii) they do not account for differences in cores obtained at targeted and systematic biopsy.
METHODS: Overall, 640 men with clinical stage T2 who underwent MRI-targeted biopsy with concomitant systematic biopsy before RP between 2016 and 2018 were identified. The Partin tables and MSKCC nomograms estimated the probability of ECE and SVI. Their discrimination was assessed using the area under the curve (AUC) method and compared to models that included also mpMRI (ECE or SVI at mpMRI and maximum lesion diameter). Two models accounting separately for the number of positive cores from targeted and systematic biopsies were developed. The AUC compared their discrimination to models based on clinical and mpMRI variables alone and to the Partin tables and MSKCC nomograms. Decision-curve analyses (DCA) determined the net-benefit associated with the use of these models.
RESULTS: Median PSA was 7.8 ng/ml. Overall, 181 (28%) patients had cT2 disease. Median mpMRI lesion diameter was 11 mm and 118 (19%) and 33 (5.2%) men had suspicious ECE and SVI. Overall, 361 (55%) and 99 (15%) patients had pathologic ECE and SVI. The AUCs of the Partin tables vs MSKCC nomograms for ECE and SVI were 61 vs 68% and 73 vs 75%. MRI parameters improved discrimination for ECE (72%) and SVI (77%). Considering separately the total number of positive cores from targeted and from systematic biopsy improved the discrimination for ECE (76%) and SVI (81%). The
